{"entity":{"id":"nct07030907","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer","aka":[],"tldr":"A phase 1 trial of OPB-101 run by Outpace Bio, Inc., terminated.","summary":"A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer is a phase 1 interventional study registered as NCT07030907 by Outpace Bio, Inc., with 3 participants enrolled, started 2025-06-16. Conditions recorded: Ovarian Cancer Recurrent, Ovarian Cancer and Platinum Resistant Ovarian Cancer. Interventions recorded: OPB-101.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07030907","url":"https://clinicaltrials.gov/study/NCT07030907"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","platinum-resistant-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["opb-101"],"companies":["outpace-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07030907","phase":"1","setting":"A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB-101, an Autologous Mesothelin (MSLN) CAR T Cell Therapy With Antigen-dependent Expression of OUTSMART™ Designed IL-2 Cytokine in Platinum-resistant Ovarian Cancer","sponsor":"Outpace Bio, Inc.","enrolled":3,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07030907/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"drug":[{"id":"opb-101","kind":"drug","name":"OPB-101","route":"/drugs/opb-101/"}],"company":[{"id":"outpace-bio","kind":"company","name":"Outpace Bio","route":"/companies/outpace-bio/"}]}}